Works Cited
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.
1. American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes--2024. Diabetes Care. 2024;47(Suppl 1):S158-S178. Diabetes Care. 2024;47(7):1238.
2. American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: Standards of Care in Diabetes--2024. Diabetes Care. 2024;47(Suppl 1):S179-S218.
3. Kelly M, Lewis J, Rao H, et al. Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: a systematic review and meta-analysis. Pharmacotherapy. 2022;42(12):921-928.
4. Hosseinpour A, Sood A, Kamalpour J, et al. Glucagon-like peptide-1 receptor agonists and major adverse cardiovascular events in patients with and without diabetes: a meta-analysis of randomized controlled trials. Clin Cardiol. 2024;47(7):e24314.
5. Neuen BL, Fletcher RA, Heath L, et al. Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis. Circulation. 2024;150(22):1781-1790.
6. Shin H, Paik JM, Everett BM, et al. Comparative effectiveness of individual sodium-glucose cotransporter 2 inhibitors. JAMA Intern Med. 2025; [Epub ahead of print].
7. Kittleson MM, Panjrath GS, Amancherla K, et al. 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81(18):1835-1878.
8. Writing Committee Members; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Card Fail. 2022;28(5):e1-e167.
9. Nicholls SJ, Bhatt DL, Buse JB, et al; SURPASS-CVOT investigators. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am Heart J. 2024;267:1-11.
10. McGuire DK, Busui RP, Deanfield J, et al. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: design and baseline characteristics of SOUL, a randomized trial. Diabetes Obes Metab. 2023;25(7):1932-1941.
11. Novo Nordisk. Oral Semaglutide Demonstrates a 14% Reduction in Risk of Major Adverse Cardiovascular Events in Adults with Type 2 Diabetes in the SOUL Trial. Available at https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=171480. Lasr accessed February 12, 2025.
12. Clinical Resource. Diabetes Medications: Cardiovascular and Kidney Impact. Pharmacist's Letter/Pharmacy Technician's Letter/Prescriber Insights. December 2024.
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.